PROKIDNEY CORP.

PROK Nasdaq CIK: 0001850270

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation Cayman Islands
Business Address 2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103
Mailing Address 2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, NC, 27103
Phone 336-999-7028
Fiscal Year End 1231
EIN 981586514

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report March 18, 2026 View on SEC
8-K Current report of material events March 18, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 12, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
8-K Current report of material events January 12, 2026 View on SEC
4 Insider stock transaction report November 14, 2025 View on SEC

Annual Reports

10-K March 18, 2026
  • Completed enrollment for REACT®'s Phase 3 pivotal trial ahead of schedule in Q3 2025, with initial safety data consistent with previous phases.
  • Developing REACT®, a novel, proprietary cell-based therapy aiming to revolutionize chronic kidney disease (CKD) treatment.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.